Progestagen-only oral contraceptives: Comparison of the metabolic effects of levonorgestrel and norethisterone

Contraception

Volumn 44, Issue 3, 1991, Pages 223-233

  Ball, MJ ^b   Ashwell, E ^a   Gillmer, MDG ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; NORETHISTERONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PRESSURE; BODY WEIGHT; FACTOR X; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HEMOGLOBINS; HUMANS; LEVONORGESTREL; LIPID METABOLISM; LIPOPROTEINS; NORETHINDRONE; PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS;

EID: 0026015210     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(91)90014-7     Document Type: Article

References (44)

1. Mortality among oral contraceptive users; 20 year follow up
2. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives
3. Oral contraceptives and death from myocardial infarction
4. Progestagens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 30μg and 50μg oestrogen preparations
5. The Royal College of General Practitioners' oral contraception study
6. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives
7. Comparison of effects of different combined oral contraceptive formulations on carbohydrate and lipid metabolism
8. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol
9. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol
10. Lipid metabolic studies in oophorectomized women Effects of three different progestagens
11. High density lipoproteins Epidemiologic profile and risks of coronary heart disease
12. The triglyceride issue. A view from Framingham
13. Improved reagent for the enzymatic determination of serum cholesterol
14. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions
15. Lipoprotein fractionation by a precipitation method
16. Determination of glucose in blood using glucose oxidase
17. A semi-automated method for the determination of glycosylated haemoglobin
18. Hereditary coagulation disorders: Laboratory techniques
19. Gerinhungsphysiologische schnellmethode zur bestimmung des fibrinogens
20. Heparin co-factor actually measured with an amidolytic method
21. Coagulation factors
22. Progestational potency of oral contraceptives
23. Sex, gonadal steroids and plasma lipoproteins
24. Comparison of the metabolic effects of two hormonal contraceptives
25. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study
26. Norethindrone acetate, post heparin lipolytic activity and plasma triglycerides in familial type I, II IV and V hyperlipoproteinaemia
27. Lipoprotein changes may be minimised by proper composition of a combined oral contraceptive
28. Effects of seven low-dose combined oral contraceptives on high density lipoprotein subfractions
29. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
30. High density lipoprotein 2 and hepatic lipase
31. The effects of progestins in combined oral contraceptives with special reference to high-density lipoproteins
32. Glucose tolerance and coronary heart disease Helsinki Policemen Study
33. Prospective studies of carbohydrate metabolism in “normal” women using norgestrel for 18 months
34. Effect of duration of low dose oral contraceptive administration on carbohydrate metabolism
35. Effects of oral contraceptives on carbohydrate metabolism
36. Effect of combined oral contraceptives on glycosylated haemoglobin
37. Haemostatic function and ischaemic heart disease principle results of the Northwick Park heart study
38. Oral contraceptives, clotting factors and thrombosis
39. Haemostatic system changes induced by 50μg and 30μg estrogen/progestagen oral contraceptives
40. Oral contraceptives and blood coagulation: A critical review
41. Experience with norethisterone 0.35mg daily as an oral contraceptive
42. A prospective study of the effect on blood pressure of contraceptive preparations containing different types and doses of progestogen
43. Risk factor changes and mortality results